美国退伍军人大型队列中持续病毒学应答后丙型肝炎病毒血症复发分析
研究从退伍军人健康管理局识别1129例直接抗病毒药物(DAA)治疗获持续病毒学应答(SVR)后仍可检出HCV病毒血症者,随机抽取110例病历审查,分为明确再感染(25.5%)、可能再感染(25.5%)、假阳性(11.8%)和推测晚期复发(37.3%)四类。中位复发时间1.9年,推测复发组肝细胞癌(HCC)比例更高(20%,P < .05)。
要点
- DAA获SVR后仍可检出HCV病毒血症,需鉴别再感染、复发与假阳性。
- 推测晚期复发组HCC占20%(P < .05),超半数复发发生在1年内。
- 年轻(18-34岁)和物质使用在明确或可能再感染中更常见。
核心结论
- 本研究加深了对HCV再感染和复发的理解,并强调HCV与阿片类药物 syndemic、实验室误差贡献、HCC中病毒储存库的可能性以及对持续风险者的临床参与意义。
研究设计与样本
- 从退伍军人健康管理局(VHA)识别1129例DAA治疗获SVR后仍可检出HCV病毒血症者,随机抽取110例进行病历审查。
- 依据实验室、诊断和病历审查数据将110例分为明确再感染(25.5%)、可能再感染(25.5%)、假阳性(11.8%)和推测晚期复发(37.3%)四类。
- 采用组间方差分析识别各类别的人口学、行为和实验室特征。
主要发现
- 病历队列(n = 1129)中物质使用和不稳定住房常见,中位复发病毒血症时间为1.9年。
- 病历审查队列(n = 110)中,年轻(18-34岁)和物质使用在明确或可能再感染中更常见。
- 推测复发组HCC比例更高(20%,P < .05),且超过半数发生在1年之前。
- 假阳性为既往未报告的特殊类别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis C virus (HCV) infection affects >1% of the US population and a larger percentage of US veterans. Direct-acting antiviral (DAA) medications achieve viral cure, termed sustained virologic response (SVR), but repeat viremia after SVR is recognized. Prior work has been limited by electronic medical record data. We aim to better understand repeat viremia in the DAA era through detailed chart review. METHODS: We identified 1129 individuals from the Veterans Health Administration (VHA) who achieved SVR using DAA therapy but subsequently had detectable HCV viremia. A random subset of 110 was chart-reviewed and assigned to 1 of the following 4 categories using laboratory, diagnosis, and chart review data: definite reinfection (25.5%), probable reinfection (25.5%), false-positive (11.8%), and presumed late relapse (37.3%). We conducted between-group analysis of variance to identify demographic, behavioral, and laboratory features specific to each. RESULTS: In our medical record cohort (n = 1129), substance use and unstable housing were common, and median time to repeat viremia was 1.9 years. In our chart review cohort (n = 110), younger age (18-34 years) and substance use were more frequent in definite or probable reinfection. Presumed relapse had comparatively more hepatocellular carcinoma (HCC; 20%, P < .05), and more than half occurred prior to 1 year. The unique category of false-positive has not previously been reported. CONCLUSIONS: This study deepens our understanding of HCV reinfection and relapse and highlights features including the HCV and opioid syndemic, contribution of laboratory error, possibility of a viral reservoir in HCC, and clinical engagement implications for those with ongoing risk.
引用
- Matelski A, Gregoire B, Beste LA, et al. Analysis of Repeat Hepatitis C Viremia After Sustained Virologic Response in a Large Cohort of US Veterans. Clin Infect Dis. 2025. PMID: 39789803. doi:10.1093/cid/ciaf008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。